Strain Name:

NMRI-Tbcepmn/J

Stock Number:

009682

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Mice that are homozygous for this Tbce, tubulin-specific chaperone e, spontaneous mutation, pmn, are viable but die prematurely. Onset of progressive atrophy and paralysis occurs at 2 to 3 weeks of age. Homozygotes die by 6 to 7 weeks of age due to respiratory failure. Neurodegeneration starts in the motor endplates, progresses to loss of axons and results in apoptosis of the cell bodies. This mutant mouse strain may be useful in studies of Spinal Muscular Atrohpy, muscular atrophy, motor neuronopathy and neurodegeneration.

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names STOCK Tbcepmn/J    (Changed: 08-FEB-11 )
Type Mutant Stock; Spontaneous Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
 
Donating Investigator Michael Sendtner,   University of Wuerzburg

Description
Mice that are homozygous for this spontaneous mutation are viable but die prematurely. Onset of locomotor impairment with corresponding motor neuron and muscular degeneration occurs at 2 to 3 weeks of age. Atrophy and paralysis starts in the hind limbs and pelvic girdle and is progressive. Homozygotes die by 6 to 7 weeks of age due to respiratory failure. Neurodegeneration starts in the motor endplates, progresses to loss of axons and results in apoptosis of the cell bodies. Electrophysiological deficiencies are detected by 13 days of age, before the neurodegeneration is clinically visible. Electron microscopic analysis of sciatic and phrenic nerves reveals a reduced number of microtubules. TBCE protein is destabilized, producing a reduction in tubulin and microtubules in motor neuron axons. Progressive microtubule loss occurs in axons distal to proximal and corresponds to axon degeneration. The mutation arose in the NMRI/Pan outbred line and has been identified as a Trp524Gly substitution (T1570G transversion) of the Tbce, tubulin-specific chaperone e, gene. Heterozygotes are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. This mutant mouse strain may be useful in studies of Spinal Muscular Atrohpy, muscular atrophy, motor neuronopathy and neurodegeneration.

Development
The mutation was first recorded at the Panum Institute (Kopenhagen, Denmark) in 1988. The mutation arose in the NMRI/Pan outbred line and has been identified as a Trp524Gly substitution of the Tbce (tubulin-specific chaperone e) gene. The donating investigator reports that these Tbcepmn mutant mice were bred onto the NMRI outbred background for 32 generations, and then Tbcepmn heterozygous males were sent to The Jackson Laboratory Repository. Upon arrival, sperm was cryopreserved from some of these Tbcepmn heterozygous mice. To rederive a living colony on the NMRI genetic background, heterozygous sperm was used to fertilize oocytes from NMRI/Gat-Tg(MGMT)3Bec/J mice (Stock No. 003076). The resulting double mutant mice will be bred together (and the Tg(MGMT)3Bec selectively bred away) to establish the Tbcepmn colony.

Control Information

  Control
   Wild-type from the colony
 
  Considerations for Choosing Controls

Related Strains

Spinal Muscular Atrophy (SMA) Models
008849   B6.129(C)-Smn1tm1.1Jme/J
006146   B6.129-Smn1tm1Jme/J
008453   B6.129-Smn1tm4(SMN2)Mrph/J
008714   B6.129-Smn1tm5(Smn1/SMN2)Mrph/J
009378   B6.129-Smn1tm6(SMN2)Mrph/J
010921   B6.129P2(Cg)-Smn1tm1Msd/J
018439   B6.129S6-Tg(CAG-Bgeo,-SMN2)E9Dscd/J
009680   B6.B-Vps54wr/J
007963   B6.Cg-Smn1tm2Mrph/J
007966   B6.Cg-Smn1tm3(SMN2/Smn1)Mrph/J
006149   B6.Cg-Tg(ACTA1-cre)79Jme/J
006663   B6.Cg-Tg(Eno2-cre)39Jme/J
008629   B6.Cg-Tg(SMN2)11Tro Smn1tm1Msd/J
008631   B6.Cg-Tg(SMN2)11Tro Tg(SMN2)46Tro Smn1tm1Msd/J
008630   B6.Cg-Tg(SMN2)46Tro Smn1tm1Msd/J
007222   B6.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN1*A2G)2023Ahmb/J
006964   B6.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb/J
006773   B6.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd/J
007246   B6;129-Smn1tm2Mrph/J
008383   B6;129-Smn1tm4(SMN2)Mrph/J
008384   B6;129-Smn1tm5(Smn1/SMN2)Mrph/J
008704   B6;129-Smn1tm6(SMN2)Mrph/J
006138   FVB.129(B6)-Smn1tm1Jme/J
008713   FVB.129(B6)-Smn1tm4(SMN2)Mrph/J
008604   FVB.129(B6)-Smn1tm5(Smn1/SMN2)Mrph/J
006214   FVB.129P2-Smn1tm1Msd/J
005058   FVB.Cg-Smn1tm1Hung Tg(SMN2)2Hung/J
008206   FVB.Cg-Smn1tm1Msd Tg(SMN2)566Ahmb/J
007955   FVB.Cg-Smn1tm2Mrph/J
007964   FVB.Cg-Smn1tm3(SMN2/Smn1)Mrph/J
009381   FVB.Cg-Smn1tm6(SMN2)Mrph/J
012252   FVB.Cg-Tbcepmn/J
006139   FVB.Cg-Tg(ACTA1-cre)79Jme/J
006297   FVB.Cg-Tg(Eno2-cre)39Jme/J
008209   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(ACTA1-SMN)69Ahmb/J
016573   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(S100B-EGFP)1Wjt Tg(SMN2*delta7)4299Ahmb/J
007968   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN1*A2G)2023Ahmb/2J
008782   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*A111G)588Ahmb/J
009134   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*A111G)591Ahmb/J
007952   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb/2J
005025   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb/J
005026   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN1*A2G)2023Ahmb/J
007949   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd/2J
005024   FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd/J
017596   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#aAhmb/J
017597   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#bAhmb/J
007022   STOCK Mnx1tm4(cre)Tmj Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb/J
008783   STOCK Tg(CAG-cre/Esr1*)5Amc Smn1tm3(SMN2/Smn1)Mrph Tg(SMN2*delta7)4299Ahmb Tg(SMN2)89Ahmb/J
005938   STOCK Tg(Eno2-cre)39Jme/J
008203   STOCK Tg(SMN2)89Ahmb Smn1tm1Msd Tg(ACTA1-SMN)63Ahmb/J
006553   STOCK Tg(SMN2)89Ahmb Smn1tm1Msd Tg(H2-K1-tsA58)6Kio Tg(SMN2*delta7)4299Ahmb/J
006570   STOCK Tg(SMN2)89Ahmb Smn1tm1Msd Tg(Hlxb9-GFP)1Tmj/J
008212   STOCK Tg(SMN2)89Ahmb Smn1tm1Msd Tg(Prnp-SMN)92Ahmb/J
018916   STOCK Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN1-SMN2*)16Cll/CllJ
007951   STOCK Tg(SMN2)89Ahmb Smn1tm3(SMN2/Smn1)Mrph Tg(SMN2*delta7)4299Ahmb/J
008359   STOCK Tg(SMN2)89Ahmb Smn1tm3(SMN2/Smn1)Mrph/J
017599   STOCK Tg(tetO-SMN2,-luc)#aAhmb/J
017600   STOCK Tg(tetO-SMN2,-luc)#bAhmb/J
View Spinal Muscular Atrophy (SMA) Models     (58 strains)

Strains carrying   Tbcepmn allele
012252   FVB.Cg-Tbcepmn/J
View Strains carrying   Tbcepmn     (1 strain)

Additional Web Information

Reference Guide to Mouse Models of Spinal Muscular Atrophy manual [.pdf]
Visit the Spinal Muscular Atrophy (SMA) Mouse Model Resource site for helpful information on SMA Disease and research resources.

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Hypoparathyroidism-Retardation-Dysmorphism Syndrome; HRD   (TBCE)
Kenny-Caffey Syndrome, Type 1; KCS1   (TBCE)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Tbcepmn/Tbcepmn

        NMRI/Pan
  • mortality/aging
  • premature death
    • mice die by 6-7 weeks of age   (MGI Ref ID J:30914)
    • survival is prolonged by injections of ciliary neutrophic factor (CNTF) delivered via an engineered CNTF construct in tranfected mouse D3 cells   (MGI Ref ID J:1717)
  • muscle phenotype
  • muscular atrophy
    • pelvic girdle and hind limb muscles atrophy and become paralytic; atrophy and paralysis of the forelimbs and respiratory musculature follow later   (MGI Ref ID J:30914)
    • skeletal muscle atrophy is caused by denervation   (MGI Ref ID J:30914)
  • progressive muscle weakness
    • in hindlimbs by the end of post-natal week three   (MGI Ref ID J:1717)
    • motor function is improved after injection of ciliary neutrophic factor (CNTF) delivered via an engineered CNTF construct in tranfected mouse D3 cells   (MGI Ref ID J:1717)
  • nervous system phenotype
  • abnormal facial nerve morphology
    • loss of motor axons here is reduced by ciliary neutrophic factor (CNTF) delivered via an engineered CNTF construct in tranfected mouse D3 cells   (MGI Ref ID J:1717)
  • abnormal phrenic nerve morphology
    • 30% of nerve fibers are lost by 28 days of age   (MGI Ref ID J:1717)
    • loss of motor axons here is reduced by ciliary neutrophic factor (CNTF) delivered via an engineered CNTF construct in tranfected mouse D3 cells   (MGI Ref ID J:1717)
  • axon degeneration
    • the motor, but not the sensory, axons of the peripheral nerves degenerate, starting at the motor endplates and dying back proximally   (MGI Ref ID J:30914)
  • motor neuron degeneration
    • progressive caudo-cranial degeneration   (MGI Ref ID J:1717)
  • respiratory system phenotype
  • respiratory failure   (MGI Ref ID J:1717)
    • mice die of respiratory failure by 6-7 weeks of age   (MGI Ref ID J:30914)
  • behavior/neurological phenotype
  • paralysis
    • detectable by 2-3 weeks of age   (MGI Ref ID J:30914)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Neurobiology Research
Neurodegeneration
Spinal Muscular Atrophy (SMA)

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tbcepmn
Allele Name progressive motor neuronopathy
Allele Type Spontaneous
Common Name(s) TbceG; pmn; progressive motor neuropathy;
Mutation Made By Michael Sendtner,   University of Wuerzburg
Strain of OriginNMRI/Pan
Gene Symbol and Name Tbce, tubulin-specific chaperone E
Chromosome 13
Gene Common Name(s) 2610206D02Rik; C530005D02Rik; HRD; KCS; KCS1; RIKEN cDNA 2610206D02 gene; RIKEN cDNA C530005D02 gene; pac2; pmn; progressive motor neuropathy;
General Note This mutation was identified in 1988 at the Panum Institute in Copenhagen.
Molecular Note The mutation has been identified as T to G transversion, resulting in a Trp524Gly amino acid substitution in the encoded protein. Northern analysis detected no difference in transcript levels between mutant and wild-type mice. That the mutation was duea defect in Tbce was demonstrated through complementation with a line expressing a Tbce transgene. [MGI Ref ID J:79895] [MGI Ref ID J:80606]

Genotyping

Genotyping Information

Genotyping Protocols

Tg(MGMT), Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Schmalbruch H; Jensen HJ; Bjaerg M; Kamieniecka Z; Kurland L. 1991. A new mouse mutant with progressive motor neuronopathy. J Neuropathol Exp Neurol 50(3):192-204. [PubMed: 2022963]  [MGI Ref ID J:30914]

Additional References

Tbcepmn related

Bommel H; Xie G; Rossoll W; Wiese S; Jablonka S; Boehm T; Sendtner M. 2002. Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J Cell Biol 159(4):563-9. [PubMed: 12446740]  [MGI Ref ID J:80606]

Bordet T; Schmalbruch H; Pettmann B; Hagege A; Castelnau-Ptakhine L; Kahn A; Haase G. 1999. Adenoviral cardiotrophin-1 gene transfer protects pmn mice from progressive motor neuronopathy. J Clin Invest 104(8):1077-85. [PubMed: 10525046]  [MGI Ref ID J:58103]

Duong F; Fournier J; Keane PE; Guenet JL; Soubrie P; Warter JM; Borg J; Poindron P. 1998. The effect of the nonpeptide neurotrophic compound SR 57746A on the progression of the disease state of the pmn mouse. Br J Pharmacol 124(4):811-7. [PubMed: 9690875]  [MGI Ref ID J:50995]

Ferrer-Alcon M; Winkler-Hirt C; Madani R; Perrin FE; Kato AC. 2008. Low intensity exercise attenuates disease progression and stimulates cell proliferation in the spinal cord of a mouse model with progressive motor neuronopathy. Neuroscience 152(2):291-5. [PubMed: 18295408]  [MGI Ref ID J:135700]

Ferrer-Alcon M; Winkler-Hirt C; Perrin FE; Kato AC. 2007. Grafted neural stem cells increase the life span and protect motoneurons in pmn mice. Neuroreport 18(14):1463-8. [PubMed: 17712275]  [MGI Ref ID J:125209]

Ferri A; Sanes JR; Coleman MP; Cunningham JM; Kato AC. 2003. Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr Biol 13(8):669-73. [PubMed: 12699624]  [MGI Ref ID J:82989]

Frey D; Schneider C; Xu L; Borg J; Spooren W; Caroni P. 2000. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 20(7):2534-42. [PubMed: 10729333]  [MGI Ref ID J:109472]

Haase G; Kennel P; Pettmann B; Vigne E; Akli S; Revah F; Schmalbruch H ; Kahn A. 1997. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors [see comments] Nat Med 3(4):429-36. [PubMed: 9095177]  [MGI Ref ID J:39440]

Haase G; Pettmann B; Vigne E; Castelnau-Ptakhine L; Schmalbruch H; Kahn A. 1998. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action. J Neurol Sci 160 Suppl 1:S97-105. [PubMed: 9851658]  [MGI Ref ID J:51340]

Haenggeli C; Kato AC. 2002. Differential vulnerability of cranial motoneurons in mouse models with motor neuron degeneration. Neurosci Lett 335(1):39-43. [PubMed: 12457737]  [MGI Ref ID J:131493]

Holtmann B; Zielasek J; Toyka KV; Sendtner M. 1999. Comparative analysis of motoneuron loss and functional deficits in PMN mice: implications for human motoneuron disease. J Neurol Sci 169(1-2):140-7. [PubMed: 10540023]  [MGI Ref ID J:58379]

Jablonka S; Holtmann B; Sendtner M; Metzger F. 2011. Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease. Exp Neurol 232(2):261-9. [PubMed: 21963648]  [MGI Ref ID J:178470]

Kennel P; Revah F; Bohme GA; Bejuit R; Gallix P; Stutzmann J; Imperato A; Pratt J. 2000. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn) J Neurol Sci 180(1-2):55-61. [PubMed: 11090865]  [MGI Ref ID J:66163]

Kennel PF; Fonteneau P; Martin E; Schmidt JM; Azzouz M; Borg J; Guenet JL; Schmalbruch H; Warter JM; Poindron P. 1996. Electromyographical and motor performance studies in the pmn mouse model of neurodegenerative disease. Neurobiol Dis 3(2):137-47. [PubMed: 9173921]  [MGI Ref ID J:43329]

Kretschmannova K; Zemkova H. 2004. Characterization of neuromuscular transmission in mice with progressive motoneuronopathy. Physiol Res 53(5):541-8. [PubMed: 15479133]  [MGI Ref ID J:118746]

Martin N; Jaubert J; Glaser P; Szatanik M; Guenet JL. 2001. Genetic and physical delineation of the region overlapping the progressive motor neuropathy (pmn) locus on mouse chromosome 13. Genomics 75(1-3):9-16. [PubMed: 11472062]  [MGI Ref ID J:70256]

Martin N; Jaubert J; Gounon P; Salido E; Haase G; Szatanik M; Guenet JL. 2002. A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nat Genet 32(3):443-7. [PubMed: 12389029]  [MGI Ref ID J:79895]

Moos T. 1995. Increased accumulation of transferrin by motor neurons of the mouse mutant progressive motor neuronopathy (pmn/pmn). J Neurocytol 24(5):389-98. [PubMed: 7650542]  [MGI Ref ID J:26671]

Perrin FE; Boisset G; Lathuiliere A; Kato AC. 2006. Cell death pathways differ in several mouse models with motoneurone disease: analysis of pure motoneurone populations at a presymptomatic age. J Neurochem 98(6):1959-72. [PubMed: 16831193]  [MGI Ref ID J:112591]

Rak K; Frenz S; Radeloff A; Groh J; Jablonka S; Martini R; Hagen R; Mlynski R. 2013. Mutation of the TBCE gene causes disturbance of microtubules in the auditory nerve and cochlear outer hair cell degeneration accompanied by progressive hearing loss in the pmn/pmn mouse. Exp Neurol 250:333-40. [PubMed: 24120439]  [MGI Ref ID J:206608]

Sagot Y; Dubois-Dauphin M; Tan SA; de Bilbao F; Aebischer P; Martinou JC; Kato AC. 1995. Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. J Neurosci 15(11):7727-33. [PubMed: 7472523]  [MGI Ref ID J:29787]

Sagot Y; Rosse T; Vejsada R; Perrelet D; Kato AC. 1998. Differential effects of neurotrophic factors on motoneuron retrograde labeling in a murine model of motoneuron disease. J Neurosci 18(3):1132-41. [PubMed: 9437033]  [MGI Ref ID J:45539]

Sagot Y; Tan SA; Baetge E; Schmalbruch H; Kato AC; Aebischer P. 1995. Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse. Eur J Neurosci 7(6):1313-22. [PubMed: 7582105]  [MGI Ref ID J:30394]

Sagot Y; Tan SA; Hammang JP; Aebischer P; Kato AC. 1996. GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice. J Neurosci 16(7):2335-41. [PubMed: 8601813]  [MGI Ref ID J:32067]

Schaefer MK; Schmalbruch H; Buhler E; Lopez C; Martin N; Guenet JL; Haase G. 2007. Progressive motor neuronopathy: a critical role of the tubulin chaperone TBCE in axonal tubulin routing from the Golgi apparatus. J Neurosci 27(33):8779-89. [PubMed: 17699660]  [MGI Ref ID J:124178]

Schmalbruch H; Jensen HJS. 1990. 'Progressive motor neuropathy' (pmn), a new neurological mutant in the mouse. Mouse Genome 87:113.  [MGI Ref ID J:14295]

Sedehizade F; Klocke R; Jockusch H. 1997. Expression of nerve-regulated genes in muscles of mouse mutants affected by spinal muscular atrophies and muscular dystrophies. Muscle Nerve 20(2):186-94. [PubMed: 9040657]  [MGI Ref ID J:53205]

Selvaraj BT; Frank N; Bender FL; Asan E; Sendtner M. 2012. Local axonal function of STAT3 rescues axon degeneration in the pmn model of motoneuron disease. J Cell Biol 199(3):437-51. [PubMed: 23109669]  [MGI Ref ID J:195255]

Sendtner M; Gotz R; Holtmann B; Thoenen H. 1997. Endogenous ciliary neurotrophic factor is a lesion factor for axotomized motoneurons in adult mice. J Neurosci 17(18):6999-7006. [PubMed: 9278535]  [MGI Ref ID J:42884]

Sendtner M; Schmalbruch H; Stockli KA; Carroll P; Kreutzberg GW; Thoenen H. 1992. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy [see comments] Nature 358(6386):502-4. [PubMed: 1641039]  [MGI Ref ID J:1717]

Simonin Y; Charron Y; Sonderegger P; Vassalli JD; Kato AC. 2006. An inhibitor of serine proteases, neuroserpin, acts as a neuroprotective agent in a mouse model of neurodegenerative disease. J Neurosci 26(41):10614-9. [PubMed: 17035547]  [MGI Ref ID J:113248]

Simonin Y; Ferrer-Alcon M; Ferri A; Kato AC. 2007. The neuroprotective effects of the WldS gene are correlated with proteasome expression rather than apoptosis. Eur J Neurosci 25(8):2269-74. [PubMed: 17445225]  [MGI Ref ID J:125019]

Simonin Y; Perrin FE; Kato AC. 2007. Axonal involvement in the Wlds neuroprotective effect: analysis of pure motoneurons in a mouse model protected from motor neuron disease at a pre-symptomatic age. J Neurochem 101(2):530-42. [PubMed: 17402973]  [MGI Ref ID J:122486]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, these mice can be bred as heterozygotes. Homozygotes are viable but die by 6 to 7 weeks of age.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2525.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We willfulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3283.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We willfulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

General Supply Notes

  • View the complete collection of spontaneous mutants in the Mouse Mutant Resource.

Control Information

  Control
   Wild-type from the colony
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.6)